We report a retrospective evaluation of the prevalence of codon 12 and 13 KRAS co-mutations in EGFR mutated NSCLC patients in progressive disease after EGFR TKI treatment as first-line therapy, with the aim to establish their prevalence and explore their impact on clinical outcome. Here, EGFR is linked to non-small cell lung carcinoma.